Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Serotonin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 7/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 7/20 | 1.00 |
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 1.00 |
| ▸ | HTR1D known ✓ | P28221 | 5/20 | 0.97 |
| ▸ | HTR7 known ✓ | P34969 | 3/20 | 0.97 |
| ▸ | HTR1B known ✓ | P28222 | 3/20 | 0.97 |
| ▸ | HTR5A known ✓ | P47898 | 2/20 | 0.97 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.97 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.97 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.97 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.97 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.97 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.97 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.97 |
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 0.97 |
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.97 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.97 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serotonin SCHEMBL25341783 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR2BNPSR1 | |
| Serotonin SCHEMBL29781387 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR2BNPSR1 | |
| Serotonin SCHEMBL8208967 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR2BNPSR1 | |
| Serotonin SCHEMBL6081529 | 0.98 | HTR2C (0.97) | HTR2CHTR2AHTR1AHTR2BNPSR1 | |
| Serotonin SCHEMBL6081535 | 0.98 | HTR2C (0.97) | HTR2CHTR2AHTR1AHTR2BNPSR1 | |
| Serotonin SCHEMBL30057954 | 0.98 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR2BNPSR1 | |
| Serotonin SCHEMBL183226 | 0.98 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR2BNPSR1 | |
| Serotonin SCHEMBL1495 | 0.98 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR2BNPSR1 | |
| Serotonin SCHEMBL29349412 | 0.98 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR2BNPSR1 | |
| Serotonin SCHEMBL396997 | 0.97 | HTR2C (0.97) | HTR2CHTR2AHTR1AHTR2BNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 783 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122063010-A | Method for identifying ploidy of corbicula fluminea and application thereof | 湖南农业大学 | 2026-05-19 | — | — | CN | claimed |
| EP-4358962-B1 | TREATMENT FOR AUTOIMMUNE DISEASES COMPRISING NALTREXONE OR A METABOLITE OR ANALOG THEREOF, A CANNABINOID AND A 5-HT RECEPTOR AGONIST | LDN PHARMA LTD (GB) | 2026-02-04 | — | — | EP | claimed |
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2025-09-11 | — | — | US | claimed |
| CN-119524805-A | Serotonin-silica microsphere compound, preparation method thereof and sialylated glycocalyx protein extraction process | 西北大学 | 2025-02-28 | — | — | CN | claimed |
| CN-119015514-A | Hemostatic and antibacterial injectable microsphere for submucosal dissection and preparation method thereof | 郑州大学 | 2024-11-26 | — | — | CN | claimed |
| CN-118765861-A | Preparation method of rat acute pharyngitis model | 河南省儿童医院郑州儿童医院 | 2024-10-15 | — | — | CN | claimed |
| US-20240293395-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | LDN Pharma Limited (GB) | 2024-09-05 | — | — | US | claimed |
| US-20240285612-A1 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | LDN Pharma Limited (GB) | 2024-08-29 | — | — | US | claimed |
| US-20240285613-A1 | TREATMENT FOR AUTOIMMUNE DISEASES | LDN Pharma Limited (GB) | 2024-08-29 | — | — | US | claimed |
| CN-118512600-A | Preparation method and antibacterial application of targeting molybdenum manganese oxide MRI (magnetic resonance imaging) nano probe | 西安医学院第二附属医院 | 2024-08-20 | — | — | CN | claimed |
| EP-2118279-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME | IPINTL, LLC (US) | 2009-11-18 | — | — | EP | claimed |
| CN-101337921-A | Method for preparing 5-hydroxytryptamine from hippophae rhamnoides | QINGHAI QINGHUA BOZHONG BIOTEC (CN) | 2009-01-07 | — | — | CN | claimed |
| WO-2008089212-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME | IPINTL, LLC (US) | 2008-07-24 | — | — | WO | claimed |
| US-20080176822-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME | CHEN CHIEN-HUNG | 2008-07-24 | — | — | US | claimed |
| CN-1166637-C | Antibacterial activity, induction, separation and synthesis of N-acyltryptamine derivative as plant protecting chemical | 中国农业大学 | 2004-09-15 | — | — | CN | claimed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | claimed |
| CN-1365971-A | Antibacterial activity, induction, separation and synthesis of N-acyltryptamine derivative as plant protecting chemical | CHINESE AGRICULTRAL UNIV (CN) | 2002-08-28 | — | — | CN | claimed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | claimed |
| WO-2000032167-A9 | A POLYSOME | SDG INC (US) | 2001-12-13 | — | — | WO | claimed |
| WO-2000032167-A1 | A POLYSOME | SDG, INC. (US) | 2000-06-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293395-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | HTR2C, HTR2B, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR1A 5/4885 |
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | VDR, OPRD1, HTR1A | HTR2C 14/4885HTR2A 11/4885HTR1A 3/4885 |
| US-20240285612-A1 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | HTR3A, HTR3C, HTR1A | HTR2C 6/4885HTR2A 10/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.